AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00833495 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOV1101-00
Description: This investigational drug is a low dose cyclosporine (also known as cyclosporine A; CsA) formulation for topical ocular administration. FOV1101-00 is presented as a solution for topical ophthalmic administration in two strengths, concentration 1 or concentration 2 w/v cyclosporine in citrate buffered aqueous vehicle. Application is intended as four times per day.
Study NCT00833495 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisolone Acetate 1% (Pred Forte®)
Description: PRED FORTE® is indicated for the treatment of steroid-responsive inflammation of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe. Instill one to two drops into the conjunctival sac two to four times daily. During the initial 24 to 48 hours, the dosing frequency may be increased if necessary. Care should be taken not to discontinue therapy prematurely.
Study NCT00833495 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: The vehicle is an eye drop that contains only the inactive ingredients of FOV1101-00.
Study NCT00833495 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The vehicle is an eye drop that contains only the inactive ingredients of FOV1101-00.
Study NCT01448473 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 4-views series
Description: The 4-film series will include the following views: anterior-posterior; one lateral; Waters, and Townes views.
Study NCT01448473 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 2-views serie
Description: The 2-film series will include the following views: anterior-posterior and one lateral.
Study NCT01226784 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Physcial activity
Description: Strenght training Relaxation exercise
Study NCT00872911 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Amino acids
Description: mixed pure crystalline amino acids for human use (Ajinomoto), 15 g/d
Study NCT00872911 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exercise
Description: progressive exercise training
Study NCT01534442 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atropine
Description: 1 mg as a bolus and the and infusion of 80 ng/kg/min for either 105 or 145 minuts.
Study NCT04128514 — intervention group
Intervention type: DEVICE
Intervention: Panoptix Toric
Description: Cataract surgery and IOL implantation
Study NCT03425461 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Anti-SEMA4D Monoclonal Antibody VX15/2503
Description: Given IV
Study NCT02283866 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Administering desflurane according to the patient's BIS value
Description: Administering desflurane according to the patient's BIS value
Study NCT02283866 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Administering desflurane at 1 MAC
Description: Administering desflurane at 1 MAC
Study NCT01892072 — intervention group
Intervention type: PROCEDURE
Intervention: surgical treatment
Description: all the patients in the study must have been treated by the surgery at the first time and have been confirmed as 'complete section' by the post-surgery radiological image.
Study NCT02967302 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Morphine Sulfate
Description: active intervention
Study NCT02967302 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Triamcinolone
Description: active control
Study NCT02967302 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo control
Study NCT04177758 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin D
Description: Patients randomized to the experimental arm of the study will receive 50,000IU of vitamin D3 following surgery and asked to take the medication orally following surgery.
Study NCT04177758 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: Patients randomized to the control will receive a placebo
Study NCT03119857 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Antiandrogen
Study NCT03119857 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antiandrogen+docetaxel
Description: Antiandrogen (bicalutamide 150 mg x 1) + docetaxel (Taxotere®) 75mg/m2 (max 2.0m2) i.v. in 60 minutes on day 1. One cycle is 21 days. Docetaxel will be given for up to 8-10 cycles or until unacceptable toxicity or consent withdrawal whichever comes first.~Antiemetic therapy may be used if necessary.
Study NCT04111445 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ADG116
Description: IV infusion at Day 1 of each cycle
Study NCT04158947 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Afatinib
Description: Dose-escalation Phase (Phase I) - Afatinib Dose-escalation will proceed on the basis of dose limiting toxicity (DLT) during Cycle 1 starting at 20 mg/day.~Dose level 1: 20 mg/day; Dose level 2: 30 mg/day; Dose level 3: 40 mg/day; Dose level 4: 50 mg/day.~Dose-evaluation Phase (Phase II) - Patients will receive the highest dose of Afatinib with T-DM1 found in Phase I as study therapy
Study NCT04158947 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: T-DM1
Description: Dose-escalation Phase (Phase I) - Trastuzumab emtansine (T-DM1) will be given at 3.6 mg/kg IV Day 1 every 21 days.~Dose-evaluation Phase (Phase II) - Trastuzumab emtansine (T-DM1) will be given at 3.6 mg/kg IV Day 1 every 21 days.
Study NCT04158947 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: T-DM1
Description: Dose-escalation Phase (Phase I) - Trastuzumab emtansine (T-DM1) will be given at 3.6 mg/kg IV Day 1 every 21 days.~Dose-evaluation Phase (Phase II) - Trastuzumab emtansine (T-DM1) will be given at 3.6 mg/kg IV Day 1 every 21 days.
Study NCT03425461 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Given IV
Study NCT03425461 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT03425461 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Given IV
Study NCT03425461 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies
Study NCT03538223 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Music Listening
Description: Participants will undergo two different types of music before radiotherapy sessions
Study NCT03538223 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: All participants will undergo radiotherapy according to breast cancer post surgery protocol
Study NCT01534442 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02649842 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TECNIS Toric Models ZCT450, ZCT525 or ZCT600
Description: Approved toric intraocular lens
Study NCT02276755 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Cholecalciferol (vitamin D3)
Description: 14000 IU vitamin D3 weekly Experimental group will receive vitamin D supplement (Tishcon, USA).
Study NCT02276755 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo group will receive placebo (Tishcon, USA) weekly.
Study NCT02090348 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dimethyl fumarate
Description: Administered as specified in the treatment arm
Study NCT04429789 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Active-Alert Hypnosis
Description: Participants in this arm will receive four one-hour weekly sessions that will include training in a rapid self-hypnosis method. Participants will learn how to use waking hypnosis to manage fatigue using exercises with sensory experiences.
Study NCT04429789 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Traditional Hypnosis
Description: Participants in this arm will receive four one-hour weekly sessions where participants will learn how to use hypnosis along with relaxation. The exercises and suggestions included in the training will be adapted from the protocol used in a series of studies on the efficacy of self-hypnosis training for the management of chronic pain in persons with disabilities, and from a therapist guide of procedures and hypnotic suggestions for chronic pain.
Study NCT03198312 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CathiportTM
Description: fully implanted
Study NCT03198312 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Implant Port
Description: fully implanted
Study NCT01633723 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DA-6886
Description: single dose study : DA-6886 1mg,2.5mg,5mg,10mg,20mg dosage (Dose-escalation)~multiple dose study : DA-6886 2.5mg,5mg,10mg or 5mg,10mg,20mg dosage (Dose-escalation)
Study NCT01633723 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo of DA-6886
Description: DA-6886 placebo
Study NCT01701817 — intervention group
Intervention type: OTHER
Intervention: Patients with Atrial Fibrillation
Description: Treatment patterns of AF according to patient demographics, clinical factors, risk stratification, and geographic regions.
Study NCT02004366 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Linagliptin
Description: Linagliptin once daily + correction doses of rapid acting insulin if needed
Study NCT02004366 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Basal Bolus
Description: Basal bolus regimen with glargine once daily and rapid-acting insulin (lispro or aspart) before meals + + correction doses of rapid acting insulin if needed
Study NCT02004366 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Linagliptin
Description: Patients with admission A1C \< 7% will be discharged on same pharmacologic regimen (oral agents, insulin therapy) or linagliptin 5 mg/day for 3 months.
Study NCT02004366 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Linagliptin + 50% Glargine dose on discharge
Description: Patients with admission HbA1c between 7% and 9% will be discharged on previous oral anti-diabetic agents plus linagliptin, and consider glargine insulin at 50% of daily hospital dose for 3 months.
Study NCT02004366 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Linagliptin + 80% Glargine
Description: Patients with admission HbA1c ≥ 9% will be discharged on previous oral anti-diabetic agents plus linagliptin, and consider glargine insulin at 80% of daily hospital dose for 3 months.
Study NCT00413946 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant human Erythropoietin
Description: 3 doses 3000 units (1 ml) of recombinant human erythropoietin per kg body weight
Study NCT00413946 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: saline
Description: three doses of 1.0 ml saline per body weight
Study NCT01921868 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetyl-L-Carnitine
Description: Acetyl-L-Carnitine, 2 g/day, up to 24 months.
Study NCT04601077 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nitric Oxide lozenges, 30 mg
Description: Nitric Oxide lozenge, 30 mg twice a day for 30 days
Study NCT04601077 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo for Nitric Oxide lozenge, 30 mg twice a day for 30 days
Study NCT01482637 — intervention group
Intervention type: OTHER
Intervention: CAS
Description: All clients will be asked to complete the CAS instrument.
Study NCT03531203 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Soursop supplementation
Description: The soursop supplementation was given to treatment group (with soursop group) 2 times a day for 100 g each for 3 months period.
Study NCT03531203 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Control group (without soursop group) was left without treatment during study period
Study NCT01964222 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Decision Aid (DA)
Description: Participants will be shown (on a computer) a targeted, web-based decision aid focused on the topic of clinical trials in addition to usual care.
Study NCT00840567 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Skin biopsy
Study NCT00840567 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Blood draw & sample
Study NCT00115700 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 1000 mg/m2 I.V. on day 1
Study NCT00115700 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radiotherapy
Description: The prescribed dose to the target volume will be 30 Gy. Daily fractions of 1.5-2.0 Gy will be employed.
Study NCT00115700 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: The prescribed dose to the target volume will be 30 Gy. Daily fractions of 1.5-2.0 Gy will be employed.
Study NCT00115700 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: 1.4 mg/m2 (maximum single dose of 2 mg) I.V. on day 1
Study NCT00115700 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisolone
Description: 50 mg/m2 orally daily for days 1 - 5
Study NCT00115700 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: 375 mg/m2 IV Infusion day 1
Study NCT01586143 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paracetamol
Description: This is a clinical study that aims to investigate and compare the efficacy of transbuccal paracetamol 125 mg with that of paracetamol 1g administered intravenously in patients with acute pain of moderate intensity accepted to emergency room following a minor trauma of the lower limbs and/or superiors. To this end, several pain scoring will be performed using a visual analogue scale (VAS) at various times after drug administration.
Study NCT01586143 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT03047668 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: diet with/without supplementation
Description: diet with/without supplementation with PUFAs
Study NCT03538223 — intervention group
Intervention type: RADIATION
Group type: OTHER
Intervention: Radiotherapy
Description: All participants will undergo radiotherapy according to breast cancer post surgery protocol
Study NCT00705614 — intervention group
Intervention type: BIOLOGICAL
Intervention: Remicade
Description: The treating physician will determine the treatment regimen and dose of Remicade.
Study NCT00911872 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: collagen (EVOLENCE)
Description: injectable collagen
Study NCT00777725 — intervention group
Intervention type: DEVICE
Intervention: FibroScan
Description: Liver scan, similar to an ultrasound.
Study NCT04988932 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inhaled nitric oxide
Description: Each increase of iNO dose is followed by a 10-minute monitoring period and a DSA examination. After reaching the highest effective dose of iNO or the maximum of 40 ppm another DSA is performed. iNO is going to be continued until normalisation of CVS or for a maximum period of 5 days. During iNO treatment a DSA will be performed every 24 hours, followed by a decrease of iNO to the next-lower level. If tapering the iNO concentration is associated with increasing vasospasm, iNO is going to be increased again to the last effective dosage. For cessation of iNO administration, dosage will be tapered every 30 minutes using the same dosage steps as for initiation of iNO treatment. If the duration of iNO treatment will be more than 32 hours, tapering intervals are prolonged to 4 hours. Cessation of iNO will be followed by a DSA.
Study NCT04202120 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Age-related stereotyping priming
Description: The priming intervention was performed using the E-prime 2.0 software (Psychology Software Tools, Pittsburgh, PA). To ensure the primes flashed on screen were beyond awareness, the similar adjustment procedure was taken (see Levy, 1996; Stein et al., 2002). After the trial block, participants were asked to try to report any words viewed during each trial. The stimulus onset asynchrony (SOA) will be reduced or enhanced whenever 2 words or above were correctly reported or no single word could be reported respectively. The priming SOA for this study ranged from 32 ms to 208 ms (M = 98.70 ms. SD = 48.60).
Study NCT04202120 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Non age-related stereotype priming
Description: he priming intervention was performed using the E-prime 2.0 software (Psychology Software Tools, Pittsburgh, PA). To ensure the primes flashed on screen were beyond awareness, the similar adjustment procedure was taken (see Levy, 1996; Stein et al., 2002). After the trial block, participants were asked to try to report any words viewed during each trial. The stimulus onset asynchrony (SOA) will be reduced or enhanced whenever 2 words or above were correctly reported or no single word could be reported respectively. The priming SOA for this study ranged from 32 ms to 208 ms (M = 98.70 ms. SD = 48.60).
Study NCT01488136 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diazoxide
Description: Diazoxide 7mg/kg, given 2 hours before the start of the clamp study
Study NCT01986257 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Emotion Regulation Group Therapy (ERGT).
Study NCT01488136 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Lactose Ph capsules (Placebo)
Study NCT03143985 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vactosertib
Description: Vactosertib is an inhibitor of protein serine/threonine kinase activity of TGF-β receptor type 1 (TGFBR1; ALK5). Vactosertib inhibits the phosphorylation of the ALK5 substrates, Smad2 and Smad3, and the intracellular signaling of TGF-β. Dosing begins at 60mg by mouth, daily and may increase to 240mg by mouth daily in the absence of dose limiting toxicities
Study NCT04180657 — intervention group
Intervention type: GENETIC
Intervention: Protein C deficiency
Description: The effect of protein C deficiency on ghrelin levels are investigated.
Study NCT04805723 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: VATS
Description: Video-assisted thoracoscopic surgery is a minimal invasive technique in which used to diagnose or treat for lung diseases. During this surgery, one or two small incisions are opened via camera and surgical instruments in patient's chest wall. Thus, less muscle and nerve tissue are damaged.~Thoracotomy is an open surgical technique in which allowing visualization of the inside of the thorax. During this surgery, an incision in patient's chest wall is made between the ribs and some muscles important for respiration are cutted to remove a part of lung.
Study NCT04805723 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Thoracotomy
Description: Thoracotomy is an open surgical technique in which allowing visualization of the inside of the thorax. During this surgery, an incision in patient's chest wall is made between the ribs and some muscles important for respiration are cutted to remove a part of lung.
Study NCT04554875 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: A scoring system
Description: The scoring system was used to rate score patients.
Study NCT03923413 — intervention group
Intervention type: OTHER
Intervention: Blood samples
Description: Blood samples for MP evaluation
Study NCT01371851 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxazosin extended release
Description: initially maintained on doxazosin extended release 4 mg once a day for 7 days, then the dose is increased to 8 mg once per day for the duration of the trial.
Study NCT01371851 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Doxazosin extended release
Description: initially maintained on doxazosin extended release 4 mg once a day for 7 days, then the dose is increased to 8 mg once per day for the duration of the trial.
Study NCT02967627 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Incisional Negative Pressure Wound Therapy (iNPWT)
Description: Incisional Negative Pressure Wound Therapy devices are lightweight, self contained, portable battery powered (or line powered), suction pumps for medical procedures where secretions and other body fluids and infectious materials must be removed through the application of continuous or intermittent negative pressure. The pumps are operated through computer software, having help and alarm features. The device is indicted for management of chronic, acute, traumatic, subacute and dehisced wounds, partial-thickness burns, ulcers (such as diabetic or pressure), flaps and grafts. The pumps may be used at patient's bedside. These are suitable for use in either hospitals or long term care facilities and nursing homes. These devices will be applied to closed laparotomy incisions with the aim to provide three days of continuous negative pressure of - 100mmHg.
Study NCT02967627 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Sterile Gauze Dressing
Description: In most cases, self-adhesive, absorbent dressings will be used for standard wound therapy. However, surgical teams may decide on alternative forms of sterile gauze dressings, as long as the wound site is kept clean and dry. Dressings should be taken down on the second post-operative day.
Study NCT00374322 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lapatinib
Description: Lapatinib 1500 mg (6 tablets) daily for 12 months
Study NCT00374322 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 6 tablets daily for 12 months